Ameritas Investment Partners’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Ameritas Investment Partners’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-174	Closed	-$5K	–	3303
2022 Q1	$5K	Hold	174	–	–	﹤0.01%	2978
2021 Q4	$8K	Hold	174	–	–	﹤0.01%	2970
2021 Q3	$14K	Hold	174	–	–	﹤0.01%	2856
2021 Q2	$16K	Buy	+174	New	+$20.6K	﹤0.01%	2840
2019 Q2	–	Sell	-3	Closed	–	–	3127
2019 Q1	$0	Hold	3	–	–	﹤0.01%	2980
2018 Q4	$0	Hold	3	–	–	﹤0.01%	3005
2018 Q3	$1K	Hold	3	–	–	﹤0.01%	3016
2018 Q2	$6K	Buy	+3	New	+$7.61K	﹤0.01%	2929

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $4.53B AUM 21.1% 1-Year Est. Return

Ameritas Investment Partners's ONCT Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2022, closing a stake of 174 shares — an estimated $5K sold.

Ameritas Investment Partners first reported a position in ONCT in Q2 2018 and held it in 8 quarters. The position peaked at $16K in Q2 2021. 75 funds tracked by Wall St. Rank hold ONCT as of Q2 2022.

Ameritas Investment Partners reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Ameritas Investment Partners sold 174 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $5K.
Ameritas Investment Partners first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2018 and held it in 8 quarters.
Ameritas Investment Partners's Oncternal Therapeutics, Inc. Common Stock position peaked at $16K in Q2 2021.
75 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.